RT Book, Section
A1 Blaha, Michael J.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193133499
T1 Treatment of High LDL Cholesterol
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193133499
RD 2024/04/24
AB Key  Clinical  Updates  in  Hyperthyroidism  (Thyrotoxicosis)The  FDA  approved  the  novel  PCSK9  inhibitor  inclisiran,  which  uses  silencing  RNA  technology  to  reduce  liver  production  of  PCSK9  protein  by  approximately  80%.  Twice-yearly  dosing  is  novel  for  lipid-lowering  therapy;  inclisiran  enables  new  delivery  strategies,  including  in-clinic  administration.Raal  FJ  et  al;  ORION-9  Investigators.  N  Engl  J  Med.  [PMID:  32197277]Ray  KK  et  al;  ORION-10  and  ORION-11  Investigators.  N  Engl  J  Med.  [PMID:  32187462]